Current Report Filing (8-k)
31 Marzo 2023 - 6:00AM
Edgar (US Regulatory)
0001454789
false
0001454789
2023-03-27
2023-03-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 27, 2023
Astria Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware |
|
001-37467 |
|
26-3687168 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification No.) |
75
State Street Suite
1400 |
|
|
Boston,
Massachusetts |
|
02109 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number, including
area code: (617) 349-1971
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, $0.001 par
value per share |
|
ATXS |
|
Nasdaq Global
Market |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 27, 2023, Dr. Andrew Nichols notified Astria Therapeutics,
Inc. (the “Company”) that he would resign from his position as Chief Scientific Officer of the Company, effective as of April
7, 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Astria
Therapeutics, INC. |
|
|
|
Date: March 31, 2023 |
By: |
/s/ Ben Harshbarger |
|
|
Ben Harshbarger |
|
|
Chief Legal Officer |
Catabasis Pharmaceuticals (NASDAQ:CATB)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about Catabasis Pharmaceuticals Inc (NASDAQ): 0 recent articles
Más de Astria Therapeutics, Inc. Artículos de Noticias